Januse Kinase Inhibition With Filgotinib to Silence Autoreactive B Cells in Rheumatoid Arthritis
Status:
Not yet recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
To investigate the effect of filgotinib on phenotype, B cell receptor (BCR) usage and
functional parameters of circulating B cells expressing ACPA in patients with ACPA-positive
RA that show incomplete response to standard, medium-dose methotrexate (MTX) monotherapy.